RxDoctor Payments Data

Ahmad Abdin, MD

Interventional Cardiology · Joplin, MONPI 1487060364

Payments from drug & device makers

$16,198in general payments, 2019–2025

Across 212 payments — averaging $76.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$8K
  • Medtronic$3K
  • Boston Scientific$1K
  • Abiomed$583
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$563
  • Amgen$389
  • plus $2K from 24 others

What the payments were for

  • Grants$1,1057%
  • Travel & lodging$8,15550%
  • Food & beverage$6,64841%
  • Education$2892%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,198 in reported general payments places this provider in the 55th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$149,628
Medicare patients
740
Services billed
2,208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban166$138,520
JardianceEmpagliflozin51$38,928
FarxigaDapagliflozin Propanediol17$21,292
BrilintaTicagrelor31$20,934
EntrestoSacubitril/Valsartan13$14,379
Praluent PenAlirocumab12$6,703
Ezetimibe99$3,189
Metoprolol Succinate154$1,781
Amiodarone Hcl79$1,553
Rosuvastatin Calcium59$1,300
ClopidogrelClopidogrel Bisulfate67$1,109
Isosorbide Dinitrate21$997
Nifedipine ErNifedipine41$984
Atorvastatin Calcium123$869
Furosemide149$756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$106$138,520166 claims
AstraZenecaFarxiga, Brilinta$174$42,22748 claims
Boehringer IngelheimJardiance$185$38,92851 claims
NovartisEntresto$61$14,37913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 182 interventional cardiology providers in Missouri.

Other interventional cardiology in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →